Orgenesis Stock (NASDAQ: ORGS) stock price, news, charts, stock research, profile.
Open | $0.507 |
Close | - |
Volume / Avg. | 6.491K / 239.990K |
Day Range | 0.500 - 0.510 |
52 Wk Range | 0.250 - 1.500 |
Market Cap | $17.169M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 42 |
Short Interest | 1.87% |
Days to Cover | 8.8 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Orgenesis (NASDAQ: ORGS) through any online brokerage.
Other companies in Orgenesis’s space includes: Vincerx Pharma (NASDAQ:VINC), Galecto (NASDAQ:GLTO), Immuron (NASDAQ:IMRN), Imunon (NASDAQ:IMNN) and Dominari Holdings (NASDAQ:DOMH).
The latest price target for Orgenesis (NASDAQ: ORGS) was reported by Benchmark on Wednesday, June 14, 2023. The analyst firm set a price target for 6.00 expecting ORGS to rise to within 12 months (a possible 1100.00% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Orgenesis (NASDAQ: ORGS) is $0.5 last updated April 22, 2024 at 7:41 PM EDT.
There are no upcoming dividends for Orgenesis.
Orgenesis’s Q1 earnings are confirmed for Wednesday, May 8, 2024.
There is no upcoming split for Orgenesis.
Orgenesis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.